Anisatin, a potent GABA antagonist, isolated from Illicium anisatum.
The neuropharmacological properties of anisatin were tested on the frog spinal cord and the crude synaptic membrane from rat brain. Anisatin (10(-5) M) reduced the amplitude of dorsal root potentials induced by stimulation of the adjacent dorsal root and presynaptic inhibition of the ventral root reflex. Anisatin shifted the dose-response curve for GABA-induced depolarization in the primary afferent terminal to the right and also reduced the maximum response to GABA. [3H]Muscimol binding to the crude synaptic membrane was not inhibited by anisatin. These results indicate that anisatin is a picrotoxin-like, non-competitive GABA-antagonist.
D000344:Afferent Pathways / Q000187:drug effects; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D001921:Brain / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005071:Evoked Potentials / Q000187:drug effects; D005727:Ganglia, Spinal / Q000187:drug effects; D007783:Lactones; D010852:Picrotoxin / Q000494:pharmacology; D010947:Plants, Toxic / Q000032:analysis*; D011892:Rana catesbeiana; D051381:Rats; D012717:Sesquiterpenes; D013116:Spinal Cord / Q000187:drug effects; D013141:Spiro Compounds / Q000302:isolation & purification* / Q000494:pharmacology; D013570:Synaptic Membranes / Q000187:drug effects
D001640:Bicuculline; D007783:Lactones; D010852:Picrotoxin; D012717:Sesquiterpenes; D013141:Spiro Compounds; C031244:anisatin